「ok」の検索結果
10件:1~5件目を表示
もしかして
-

論文投稿実績 | 研究開発活動 | 千寿製薬株式会社
n channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satoko Doi1, Mana Okada1, Satomi Kikuchi2, Yoshihisa Nakano2, Shigeki Matsumoto2, Gen Suzuki1, Ikuyo At...
https://www.senju.co.jp/rd/thesis/ -

发表论文 | 研究与开发 | 千寿制药株式会社
n channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satoko Doi1, Mana Okada1, Satomi Kikuchi2, Yoshihisa Nakano2, Shigeki Matsumoto2, Gen Suzuki1, Ikuyo At...
http://www.senju.co.jp/chinese/rd/thesis/ -

Product Development Policy | Research & Development | SENJU Pharmaceutica
Creator**” and our greatest strength: the power of “the solidarity of the entire company.” As we look ahead to developing a diverse range of products, we will draw on the spirit of every individual “...
http://www.senju.co.jp/english/rd/policy/ -

产品开发方针 | 研究与开发 | 千寿制药株式会社
pulation. 2024. #4: 横井则彦,加藤弘明:干眼症诊疗范式的变化 眼表面的分层诊断和分层治疗.京府医大期刊,2013 122(8):549-57 #5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analysis of cor...
http://www.senju.co.jp/chinese/rd/policy/ -

製品開発方針 | 研究開発活動 | 千寿製薬株式会社
n. 2024. #4:横井則彦,加藤弘明:ドライアイ診療のパラダイムシフト 眼表面の層別診断・層別治療.京府医大誌, 2013 122(8) : 549-57 #5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analysis of cor...
https://www.senju.co.jp/rd/policy/